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Role of Inflammation in Initiation
and Perpetuation of Atrial Fibrillation
A Systematic Review of the Published Data
Tim T. Issac, MD, Hisham Dokainish, MD, FACC, Nasser M. Lakkis, MD, FACC
Houston, Texas
Atrial fibrillation (AF) is the most common arrhythmia in clinical practice. Recent studies have indicated that in-
flammation might play a significant role in the initiation, maintenance, and perpetuation of AF. Inflammatory
markers such as interleukin-6 and C-reactive protein are elevated in AF and correlate to longer duration of AF,
success of cardioversion, and thrombogenesis. Furthermore, the inflammatory process might be modulated by
the use of statins, angiotensin-converting enzyme inhibitors, or glucocorticoids. The purpose of this study is to
analyze the current published reports on the relationship between inflammation and AF and the potential thera-
peutic options available to modulate the inflammatory milieu in AF. (J Am Coll Cardiol 2007;50:2021–8)
© 2007 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.06.054P
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Atrial fibrillation (AF) is the most common arrhythmia in
linical practice. It is often rapid, irregular, and might arise
rom multiple ectopic atrial foci (1,2). Twenty percent of
atients with paroxysmal atrial fibrillation (PAF), defined as
asting 7 days (and spontaneous conversion), progress to
hronic (persistent or permanent) AF, defined as lasting
30 days (1,2–5). The prevalence of AF—affecting more
han 2.3 million people in the U.S.—increases dramatically
ith age and is seen in as high as 9% of individuals by the
ge of 80 years (1). In high-risk patients, the thromboem-
olic stroke risk can be as high as 9% per year and is
ssociated with a 2-fold increase in mortality (1,2). The
urpose of this study is to analyze the current published
eports on the role of inflammation in the perpetuation and
aintenance of AF and potential therapeutic options avail-
ble to modulate this inflammatory process.
ethods
comprehensive search of published reports with PubMed
as done on the topics of AF and inflammation. Additional
ey words included interleukin (IL)-6 and C-reactive pro-
ein (CRP). Criteria for consideration were abstracts and
ournals written in English between 1995 and 2007. A total
f 65 journal articles were reviewed in this paper. Emphasis
as placed on abstracts and journals linking AF to inflam-
ation and potential treatment modalities such as statins,
ngiotensin-converting enzyme (ACE) inhibitors, and glu-
ocorticoid therapy.
rom the Division of Cardiology, Baylor College of Medicine, Houston, Texas.f
Manuscript received April 30, 2007; revised manuscript received June 13, 2007,
ccepted June 19, 2007.athophysiology
lthough the pathophysiological mechanism underlying the
enesis of AF has been the focus of many studies, it only
emains partially understood. Conventional theories focused
n the presence of multiple re-entrant circuits originating in
he atria that are asynchronous and conducted at various
elocities through tissues with various refractory periods (2).
ecently, rapidly firing atrial activity in the muscular sleeves
round the pulmonary veins ostia have been described as
otential mechanism for AF (3).
The development of AF leads to structural and electrical
hanges in the atria, a process known as remodeling. These
hanges further perpetuate the existence and mainte-
ance of this arrhythmia (i.e., “atrial fibrillation begets
trial fibrillation”) (4). Electrical remodeling has been
eported to begin within a few hours after the onset of
F, whereas the structural changes begin to develop after
everal weeks, thus cardioversion after 24 h becomes
ncreasingly difficult (5).
Much attention has been devoted in the past few years to
ssess the role of inflammation in AF. The contribution of
he inflammatory cascade to the onset of AF is suggested
y the high incidence of AF in post-operative cardiac
urgeries, a state of intense inflammatory process (6,7,8).
ther studies have suggested that inflammation leads to
atrial myocarditis” with subsequent electrical and struc-
ural atrial changes, resulting in initiation and mainte-
ance of AF (5,9). Also left atrial dysfunction has been
escribed in patients with increased CRP but without
F, suggesting that inflammation per se affects left atrial
unction (10).
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Cytokines are intracellular poly-
peptides produced by activated
cells, usually monocytes and
macrophages, in response to in-
flammatory stimuli. They are
paramount in activating the in-
flammatory cascade and in the
production of acute-phase pro-
teins. The primary inflammatory-
mediated cytokines include IL-6,
tumor necrosis factor (TNF)-,
IL-1, interferon (IFN)-, trans-
forming growth factor (TGF)-,
and IL-8. Interleukin-6, however,
is the primary stimulator of
acute-phase proteins. One such
acute-phase protein that is the
center of much research is CRP.
Measurement of acute-phase
proteins, such as CRP, can provide
a window into the current inflam-
matory status of a patient (6–9).
Many studies have related an
increase in CRP and IL-6 in
both PAF and persistent AF (9–
12). Studies have already corre-
ated elevation of CRP in healthy individuals to an increased
uture risk of cardiovascular disease, cerebral vascular events,
nd peripheral arterial disease (13–16). Elevation of CRP
nd IL-6 might also contribute to generation and perpetu-
tion of AF, as evidenced by marked inflammatory infil-
rates, myocyte necrosis, and fibrosis found in atrial biopsies
f patients with lone AF (7–11). Complement activation
as also been described in a cohort of patients with AF
ithout other associated inflammatory diseases (8). It has
een suggested in 1 population-based cohort of 1,011
atients who were followed up to 4 years that, in the absence
f high baseline complement component levels (C3 and
4), a high baseline CRP level is not significantly associated
ith a high incidence of AF (17).
The exact mechanism of inflammation leading to tissue
emodeling in AF patients is unclear and warrants further
esearch. It is thought that AF leads to myocyte calcium
verload, promoting atrial myocyte apoptosis. C-reactive
rotein might then act as an opsonin that binds to atrial
yocytes, inducing local inflammation and complement
ctivation. Tissue damage then ensues and fibrosis sets in
9,16,18). Specifically, in the presence of Ca2 ions, CRP
inds to phosphatidylcholine. Long-chain acylcarnitines
nd lysophosphatidylcholines are generated from phos-
hatidylcholine and can further contribute to membrane
ysfunction by inhibiting the exchange of sodium and
alcium ions in sarcomeres. This can eventually lead to the
Abbreviations
and Acronyms
ACE  angiotensin-
converting enzyme
AERP  atrial effective
refractory period
AF  atrial fibrillation
ARB  angiotensin
receptor blocker
CABG  cardiac bypass
surgery
CRP  C-reactive protein
DCCV  direct current
cardioversion
IFN  interferon
IL  interleukin
PAF  paroxysmal atrial
fibrillatioin
RAS  renin-angiotensin
system
SEC  spontaneous echo
contrast
TGF  transforming growth
factor
TNF  tumor necrosis
factoraintenance of AF (9,16,17). AF in post-operative inflammation. The inflammatory
ascade and catecholamine surge associated with surgery
ight play a prominent role in initiating atrial tachyarrhyth-
ias after cardiac surgery. It has been reported to occur in
p to 40% of patients undergoing cardiac bypass surgery
CABG) or up to 50% of patients undergoing cardiac
alvular surgery (3,4). After cardiac surgery, the comple-
ent system is activated and pro-inflammatory cytokines
re released. Bruins et al. (8) found that IL-6 rises initially
nd peaks at 6 h after surgery and a second phase occurs in
hich CRP levels peak on post-operative day 2, with
omplement-CRP complexes peaking on postoperative day
or 3. The incidence of atrial arrhythmias follows a similar
attern and peaks on post-operative day 2 or 3 (4–8).
nother study correlated leukocytosis to an increased inci-
ence in AF in post-operative cardiovascular patients (18).
At a molecular level, Burzotta et al. (19) discovered that
he development of postoperative AF was linked to 174G/C
olymorphism of the IL-6 promoter gene. In this particular
tudy of 110 patients undergoing CABG, genetic analysis
evealed that the GG genotype was associated with higher
L-6 plasma levels and, subsequently, a greater inflamma-
ory burden. Similarly Gaudino et al. (20) established a
enetic link between inflammation and AF and found that
he GG genotype was an independent predictor of post-
perative AF.
F in nonoperative inflammation. Current evidence sug-
ests that inflammation might also play a prominent role in
oth the etiology and maintenance of nonoperative onset of
F (21). Numerous studies (Table 1) have reported specif-
cally on the association of CRP with the development and
aintenance of AF. The study by Chung et al. (10) was one
f the first to demonstrate an association in elevated CRP
evels with the onset of AF in a nonoperative setting. The
RP levels were more than 2-fold higher in patients with
F than in the control subjects. Furthermore, patients with
ersistent AF had higher CRP levels than those with PAF,
uggesting that inflammation plays a role in the mainte-
ance of AF.
Around the same time, Dernellis and Panaretou (16)
eported similar results. They demonstrated that CRP
levation was present in patients with PAF and that CRP
evels were higher in patients who failed cardioversion with
miodarone. Many studies have since drawn similar conclu-
ions (Table 1), thus validating the notion that inflamma-
ion plays a viable role in the perpetuation and maintenance
f AF. It is now known that CRP levels in patients with
ersistent AF are higher than in those with paroxysmal AF,
nd levels in both groups are higher than those in the
ontrol group (9,16). Moreover, lower CRP levels have also
een correlated to increased success rate of electrical cardio-
ersion and subsequent maintenance of normal sinus
hythm (16,21–28). Dernellis and Panaretou (22) reported
hat for every 1-mg/dl increase in serum CRP, the risk for
ecurrent AF is increased 7 times and the risk for permanent
F is 12 times greater than control. Currently, it remains
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November 20, 2007:2021–8 Inflammation in AFnclear whether inflammation is a cause of AF or merely a
onsequence. Sata et al. (27) attempted to establish causality
etween inflammation and onset of AF in 15 patients with
AF who were enrolled into a study where CRP, IL-6, and
NF- were measured at 3 separate time intervals: baseline,
4 h, and 2 weeks after cardioversion and compared with 11
atients with normal sinus rhythm. Baseline CRP, IL-6,
nd TNF- were greater (0.145 vs. 0.035, p  0.05) in the
F group and did not normalize 2 weeks after cardiover-
ion. Although the sample size is limited, the study provided
nsight into the role of the inflammatory process in AF and
uggested that inflammation might be an independent risk
actor for AF.
nflammation and Thrombosis
ot only has inflammation been linked to AF, but it is also
hought to contribute to thrombogenesis (Table 2). Inflam-
atory markers such as CRP and IL-6 are markedly
levated in patients with dilated left atrium and a poorly
unctioning left atrial appendage (12). This subgroup of
atients is more likely to have spontaneous echo contrast
SEC) and/or thrombus in the left atrial appendage (22).
atients with longer duration in AF had a greater elevation
n CRP levels and subsequently greater atrial structural
emodeling (12,29), as evident by larger left atrial diameter.
urthermore, inflammation might promote the formation
f SEC by enhancing platelet activation (22), promoting
F in Non–Post-Operative Patients
Table 1 AF in Non–Post-Operative Patients
Author Study Design
Aviles et al. (9) Cross-sectional and
longitudinal
Cros
5
l
A
Chung et al. (10) Retrospective, case
control subjects
131
7
Dernellis and Panaretou (16) Prospective, case control
subjects
50 s
5
Dernellis and Panaretou (22) Prospective, interventional
with follow-up up to
30 months
52 r
(
5
Anderson et al. (23) Retrospective analysis of
a prospective registry
347
g
Watanabe et al. (24) Prospective, interventional
with follow-up up to
12 months after
cardioversion
104
c
Conway et al. (25) Prospective 54 p
4
Asselbergs et al. (26) Cross-sectional 8,50
Sata et al. (27) Prospective 15 P
w
c
c
a
1
F  atrial fibrillation; CRP  C-reactive protein; IL  interleukin; NSR  normal sinus rhythm; Pndothelial damage, and increasing interaction between platelets and neutrophils—a process that is integral in the
athway of thrombus formation (30). Markers of platelet
ctivation as assessed by soluble P-selectin levels have
een shown to be elevated within 12 h in patients with
AF and return to normal upon resolution to normal
inus rhythm (20).
Yamashita et al. (31) found that rapid atrial pacing over
everal hours in rats downregulated the genetic expression of
ntrinsic anticoagulant thrombomodulin (TM) and tissue
actor pathway inhibitor (TFPI) in the atrial endocardium.
hese proteins provide natural anticoagulant activity on the
nternal surface of the atrium and diminished atrial endo-
helial activity leading to thrombogenesis by inducing a
ypercoagulable state and an imbalance in the coagulation
ascade.
Multiple investigators (25,30–34) have reported on find-
ng an association between inflammatory markers in AF and
hrombogenesis (Table 2). In 1 study, patients with persis-
ent AF were recruited for transesophageal echocardiogra-
hy (TEE). The CRP levels, soluble P-selectin, and hemat-
crit were higher in AF patients with SEC than those
ithout AF (35). In another retrospective study, CRP and
L-6 levels were measured in patients with AF and were
ollowed up to 6 years (30). In this particular study, elevated
L-6 was an independent predictor of stroke and the
omposite end point of stroke or death. Although not
tatistically significant, the CRP level trend was higher in
Subjects Results
ional analysis of
F patients and
inal study of 5,491
ents
1) CRP associated with presence of AF; 2) CRP
also predicts patients at increased risk for
future development of AF
erimental and
ntrol
1) CRP elevated in AF; 2) CRP was greater in
persistent AF than PAF
atients with PAF and
rol subjects
1) CRP elevated in AF; 2) CRP inversely related
to successful cardioversion rate
d methylprednisolone
rdioversion) and
ntrol
1) Methylprednisolone prevents recurrent AF
F, 2,449 in control 1) CRP elevated with AF
lectrical
ersion
1) CRP level before cardioversion represents an
independent predictor of both successful
cardioversion and maintenance of SR after
electrical cardioversion
s with AF and
rol subjects
1) CRP levels were predictor of cardioversion
outcome
ients 1) CRP and microalbuminuria are independent
risk factors for AF; 2) both factors together
represent a 4-fold higher risk
which blood work
tained before
ersion, 24 h after
ersion, and 2 weeks
rdioversion;
rol patients (in NSR)
1) Levels of CRP, IL-6, and TNF- were markedly
more elevated than the control group;
2) CRP, IL-6, and TNF- did not change once
restoration of NSR, thus inflammation must
in part be a cause of AF
roxysmal atrial fibrillation; TNF  tumor necrosis factor.s-sect
,806 A
ongitud
F pati
in exp
1 in co
tudy p
0 cont
eceive
post-ca
2 in co
with A
roup
with e
ardiov
atient
1 cont
1 pat
AF in
as ob
ardiov
ardiov
fter ca
1 contatients with stroke (26,30–33).
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Inflammation in AF November 20, 2007:2021–8nflammation in AF and Pharmacotherapy
tatin therapy. Statins are well-known for their lipid-
owering ability and consequently their cardioprotective effects.
he reduction of cholesterol via activity at the
-hydroxymethylglutaryl-coenzyme A (HMG-CoA) is well-
stablished, and its effect on reducing cardiovascular events has
een well documented. It is now thought that their cardiopro-
ective effects can at least partially be explained by their so
alled “pleiotropic effect” (Table 3). In a study by Nissen et al.
34), CRP levels were dramatically reduced from baseline in
he 80-mg atorvastatin group compared with 40-mg pravasta-
in group (36.4% vs. 5.2%, p  0.001), suggesting that statins
ight possess some anti-inflammatory properties.
The exact mechanism of how statins exert their pleiotropic
ffects is not well understood and is the current focus of much
esearch (35). In vitro studies have suggested that stabilization
f endothelial cells offer a partial explanation for its nonlipid-
owering effects. Leukocyte adhesion to the endothelium oc-
urs early on in atherosclerosis and is mediated by the release of
ytokines. Statins have been found to selectively inhibit
eukocyte-function antigen (LFA)-1 and intercellular adhesion
olecule (ICAM)-1, paramount for the process of adhesion of
F and Echocardiographic Findings
Table 2 AF and Echocardiographic Findings
Authors Study Design
LA size
Psychari et al. (12) Prospective
Watanabe et al. (29) Prospective
Thrombosis
Conway et al. (25) Cross-sectional
Conway et al. (30) Retrospective
Roldan et al. (32) Cross-sectional
Conway et al. (33) Cross-sectional
A  left atrium; L-PAF  long paroxysmal atrial fibrillation; SEC  spontaneous echo contrast; S-
s in Table 1.nflammatory cells to the endothelium (36). Other studies havehown that statins can also diminish migration and prolifera-
ion of leukocytes to endothelial membrane and even induce
poptosis in smooth muscle cells, endothelial cells, and mac-
ophages, while reducing inflammation through suppression of
RP and IL-6 (35–38).
Whereas statins primary role is to reduce cholesterol
ormation by suppressing the formation of mevalonate, it is
hrough the inhibition of mevalonate that the other pleio-
ropic effects of statins are observed. Inhibition of meval-
nate diminishes the production of isoprenoids such as
arnesyl pyrophosphate (FPP) and geranylgeranyl pyrophos-
hate (GGPP), which are integral in the prenylation process
Subjects Results
90 patients with
persistent and
permanent AF;
46 control patients
1) IL-6 and CRP participate in evolution of
AF; 2) LA size correlates with CRP and
IL-6 levels
50 PAF patients split into
2 groups on the basis
of duration of AF:
S-PAF (30 days) and
L-PAF (30 days)
1) CRP elevated in PAF vs. control group;
2) L-PAF had higher CRP levels than
S-PAF; 3) both S-PAF and L-PAF had
larger LA diameter than control
subjects; 4) L-PAF S-PAF in LA size;
5) cannot deduce actual causality of
CRP to atrial remodeling
106 chronic AF patients
with 41 control
subjects
1) Increased IL-6, CRP, plasma viscosity
are elevated and correlate to a
prothrombotic state; 2) no correlation
was seen with von Willebrand,
P-selectin
77 AF patients who were
followed for
approximately 6 yrs
1) High IL-6 and CRP were independent
predictors of stroke and composite end
point of stroke or death
191 patients with AF and
74 in NSR
1) IL-6 and factor 1  2 elevated in AF
patients; 2) no correlation to future
thrombotic events
37 patients with
persistent AF and
37 control patients
1) CRP, soluble P-selectin, and hematocrit
were higher among AF patients with
dense SEC than those patients with AF
and without dense SEC; 2) CRP levels
elevated in AF patients with complex
atheromatous plaque; 3) AF patients
with 1 TEE risk factor for
thromboembolism had higher CRP
levels
hort paroxysmal atrial fibrillation; TEE  transesophageal echocardiography; other abbreviations
leiotropic Effects of Statins on the Endothelium
Table 3 Pleiotropic Effects of Statins on the Endothelium
2 Adhesion
2 Migration
2 Proliferation
1 Endothelial function
2 Matrix degradation
2 Apoptosis
2 ThrombosisPAF  s2 Inflammatory cascade
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November 20, 2007:2021–8 Inflammation in AFf signal transducers, such as G-proteins, Rho, and Ras.
hus, protein–protein interactions needed for initiation of
nflammatory-mediated pathways are interrupted (35–38).
NIMAL STUDIES. Initial studies in dogs have found that
torvastatin prevents AF by inhibiting inflammation in a
anine sterile pericarditis model (39). The CRP levels were
ecreased, atrial effective refractory period (AERP) was in-
reased, atrial conduction time decreased, and AF duration was
iminished in the atorvastatin arm on post-operative day 2. In
nother similar study in a canine model of inducing AF by
apid atrial pacing, simvastatin-treated dogs had longer AERP
nd consequently shorter duration of AF (40).
LINICAL TRIALS. Very few studies of statin therapy in
atients with AF have been published (Table 4). One of the
rst studies to report a beneficial effect of chronic statin use
n AF was a retrospective analysis of the recurrence rate of
ersistent lone AF in 62 patients receiving statin therapy
ndergoing direct current cardioversion (DCCV). Patients
eceiving chronic statin therapy had a lower recurrence rate
fter DCCV (40% vs. 84%, p  0.007) at an average
ollow-up of 44 months, with the benefit of statin therapy
eaching clinical and statistical significance after 3 to 4
onths of therapy (Table 4). Not all patients in this trial
ad evidence of structural heart disease (41). These
esults could not be duplicated in 114 patients undergo-
ng DCCV on pravastatin therapy (42). The different
utcomes between these 2 studies might be explained by the
imited duration and dosage of statin therapy before and after
CCV and by the greater percentage of patients that had
tructural heart disease in the latter study. Another possibility
s the innate difference in the ability of different statins to
ttenuate inflammation.
Another study by Young-Xu et al. (43) examined 449
atients with coronary artery disease in sinus rhythm and
ollowed them prospectively for up to 5 years to assess the
ncidence of AF while receiving a statin of any brand. Eight
ercent of regular-statin users (p  0.01), 10% of
nflammation in AF and Statin Therapy
Table 4 Inflammation in AF and Statin Therapy
Author (Ref. #) Study Design
Siu et al. (41) Retrospective 62 lon
10
52
me
44
Tveit et al. (42) Prospective 114 p
to p
vers
Young-Xu et al. (43) Prospective 449 p
wer
app
Dernellis and Panaretou (44) Prospective 80 pa
ran
ato
nonAD  coronary artery disease; EC  electrical cardioversion; other abbreviations as in Table 1.ntermittent-statin users (p  0.11), and 15% of nonstatin
sers developed AF over the course of 5 years. These results
ere independent of the lipid-lowering effects of statin,
uggesting that the pleiotropic effect of statins might have
ontributed to the reduction in AF.
In a more recent study, Dernellis and Panaretou (44)
xamined the effects of atorvastatin in patients with PAF.
ighty patients were randomized into 40 mg of either atorva-
tatin or placebo. In the atorvastatin arm, CRP levels were
ower (decreased by 2.4 from baseline, p 0.01) and resolution
f PAF was seen in 26 of 40 patients (p  0.01) at 6-month
ollow-up. This study further supports the notion that CRP
an be considered as an independent risk factor for AF.
The overall results of these trials support the idea that
tatin therapy might affect the natural history of AF by
meliorating the inflammatory process.
lucocorticoids. Most of the initial studies involving glu-
ocorticoid therapy in AF were done in patients undergoing
ardiovascular surgery, and the results were equivocal. Early
tudies by Chaney et al. (45) did not find any significant
enefit to steroid administration to patients undergoing
ABG; however, Yared et al. (46) in a study of 216 patients
ndergoing cardiothoracic surgery found that dexametha-
one administration perioperatively decreased the incidence
f post-operative AF in the first few days after surgery.
nflammatory markers (i.e., CRP, IL-6, and so forth) were
ot measured in this study. More recently, Yared et al. (47)
eported on the outcome of 78 patients undergoing combined
ABG and valve surgery, who were randomized to receive
ither dexamethasone or placebo before surgery. In this study,
examethasone did not affect the incidence of perioperative
F. However, it did modulate the release of several inflam-
atory and acute-phase response mediators that are associated
ith adverse outcomes. Most recently, another group from
inland showed in a prospective, randomized, double-blind
tudy that the use of 100 mg cortisone, given intravenously
mmediately before cardiac surgery and continued for 3 con-
ects Conclusion
istent AF,
d statin and
control;
ow-up
s
1) Those patients taking statin had lower recurrence
of AF after EC than control subjects (40% vs.
84%); 2) first clinical trial on recurrence of AF
after EC; 3) effects of statin were seen after a
few months of therapy
randomized
atin 40 mg
ne
1) Pravastatin therapy did not reduce the recurrence
rate of AF after electrical cardioversion
with CAD
wed for
tely 5 yrs
1) 9% of regular-statin users developed AF, 10% of
intermittent-statin users developed AF, and 15%
of non-statin users developed AF; 2) statin effect
was independent of lipid-lowering ability
ith PAF
d to 40 mg
in versus
1) Treatment group had lower CRP levels at follow-up;
2) treatment group had decreased number of
PAF events; 3) 65% (26 of 40) in treatment
group had resolution of PAFSubj
e pers
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in the
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Inflammation in AF November 20, 2007:2021–8ecutive days, significantly decreases the incidence of AF after
ardiac surgery by 15% (48).
One major prospective trial examined the effects of
dding methylprednisolone to propafenone in AF patients
ndergoing pharmacological cardioversion to assess the
ecurrence rate. The methylprednisolone-treated group ex-
erienced an 80% decrease in CRP levels (p 0.001) within
he first month, which was maintained throughout the
uration of the study. This corresponded to a reduction of
F recurrence from 50% in the placebo group to 9.6% in the
ethylprednisolone group (p  0.001) (22).
ngiotensin-converting enzyme inhibitors (ACE-Is).
ngiotensin-converting enzyme inhibitors and angiotensin
eceptor blockers (ARBs) are 2 classes of drugs that act on
he renin-angiotensin system (RAS). The RAS is intimately
nvolved in the pathophysiology of various cardiovascular
iseases such as hypertension, congestive heart failure, and
schemic heart disease. Studies have now linked the RAS
ene polymorphisms to the development of AF (49). These
esults might indicate that angiotensin II might be involved
n atrial structural and electrical remodeling in patients with
F (50).
The inhibition of the RAS and consequently of angio-
ensin II might have protective effect on remodeling (51,52).
t is known that angiotensin II is a potent promoter of atrial
brosis by stimulating mitogen-activated protein kinases
nd extracellular signal-related kinase, which contributes to
brosis formation and AF duration via expression of
GF- (53). Furthermore, angiotensin II also increases
trial pressure, leading to greater atrial stretch, which
educes AERP and increases intra-atrial conduction time—
ll of which are factors in the initiation and maintenance of
CE-Is/ARBs and AF
Table 5 ACE-Is/ARBs and AF
Trial (Ref. #) Study Design
Electric cardioversion Madrid et al. (56) Prospective Group
ami
Zaman et al. (58) Prospective 24 in A
con
Ueng et al. (59) Prospective Group
ami
Post-MI Pedersen et al. (61) Prospective Trando
follo
Heart failure SOLVD (62) Prospective study,
but retrospective
analysis
186 on
follo
3 yr
Val-HeFT (64) Prospective study,
but retrospective
analysis
4,409
CHARM (65) Prospective study,
but retrospective
analysis
5,518
app
Hypertension Hirayama et al. (57) Retrospective 42 trea
follo
L’Allier et al. (60) Retrospective 5,463
cha
appCE-I  angiotensin-converting enzyme inhibitor; AERP  atrial effective refractory period; AF  atrial
yocardial infarction; SOLVD  Studies Of Left Ventricular Dysfunction; Val-Heft  Valsartan Heart FailuF. Furthermore, it is now postulated that ACE-Is/ARBs
an modulate potassium and calcium ion channels, amelio-
ating the deleterious effects of both atrial structural and
lectrical remodeling (50,51).
NIMAL STUDIES. Much of our current understanding of
CE-Is and their effect on AF originates from research on
anine models with either rapid atrial or ventricular pacing
51,54,55) to induce AF and/or heart failure, respectively.
he ACE-I–treated dogs consistently had longer AERP,
horter AF duration, diminished atrial apoptosis, and less
trial remodeling. Similar effects were not seen in dogs
reated with hydralazine and isosorbide mononitrate, sug-
esting that the inhibition of the RAS (via ACE-I) might
e responsible for the attenuated atrial electrical and struc-
ural remodeling (52).
UMAN STUDIES. There are only a few prospective human
rials that correlate whether ACE-Is/ARBs can modulate
he duration or onset of AF (56) (Table 5). However, post
oc analysis of large, randomized ACE-I trials provided an
pportunity to study their effects on development of AF.
LINICAL TRIALS IN PATIENTS WITH NORMAL EJECTION
RACTION. In 1 particular retrospective study, hypertensive
atients with PAF were treated with ACE-I and followed
or up to 8 years (Table 5). The ACE-Is were found to
revent the progression of PAF to chronic AF (57). Two
ther prospective trials found benefit in ACE-I use on
ncidence of AF. One study found that the addition of
nalapril to amiodarone in patients undergoing DCCV had
ower recurrence of AF (4.3% in amiodarone with ACE-I
s. 14.7% in amiodarone alone, p  0.067) and maintained
Subjects Results
iodarone only; Group 2 
e  irbesartan
1) Recurrence of AF lower in Group 2
rm and 23 in other
up
1) Number of defibrillation of attempts required
for successful cardioversion less in ACE-I arm
iodarone only; Group 2 
e  enalapril
1) Group II had decreased rate of acute and
subacute recurrence of AF
rm  790; control  787;
ver period of 2–4 yrs
1) Trandolapril reduces AF in patients with
LV dysfunction post-MI
pril and 188 in control;
n average for approximately
1) ACE-I helps prevent AF in patients with
depressed LV function
ized and followed for 2 yrs 1) Patients on ARB had lower incidence of AF
ized and followed for
tely 3 yrs
1) ARB helps reduce incidence of AF in both
normal and depressed ejection fraction
ith ACE-I and 53 in control;
or approximately 8 yrs
1) ACE-I can prevent progression of PAF to
chronic AF
-I arm and 5,463 in calcium
lockers; followed on average
tely 4.5 yrs
ACE-I arm: 1) lower incidence of AF; 2) amount of
time to onset of AF is longer; 3) decreased
hospital stays due to AF1  am
odaron
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trol gro
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November 20, 2007:2021–8 Inflammation in AFonger duration of sinus rhythm (58). In another study, the
otal number of cardioversion attempts for AF were lower
24 in ACE-I vs. 34 in calcium channel blockers, p 
.001) and the number of hospital stays for AF were fewer
p  0.02) in the ACE-I group (59). In another retrospec-
ive analysis by L’Allier et al. (60) on 10,926 patients treated
ith either ACE-I or calcium channel blockers for AF,
hose in the ACE-I arm had lower incidence of new-onset
F, longer time to onset of AF, and fewer hospital stays as
consequence of AF.
LINICAL TRIALS IN PATIENTS WITH LEFT VENTRICULAR
YSFUNCTION. Retrospective analysis of large scale ran-
omized trials suggest that ACE-I might have some benefit
n reducing incidence of AF in patients with depressed
jection fraction (Table 4). In the TRACE (Trandolapril
ardiac Evaluation) trial (61), 2.8% of patients in the
randolapril arm developed AF versus 5.3% (p  0.05) in
he placebo arm; similarly, patients randomized to enalapril
n SOLVD (Studies Of Left Ventricular Dysfunction) (62)
ad a 78% relative risk reduction in developing AF (p 
.0001).
RBs. There are a few studies linking reduction in AF
ith an administration of an ARB (Table 5). In 1 prospec-
ive study, addition of irbesartan to amiodarone resulted in
ower recurrence of AF after DCCV in patients with normal
jection fraction (79.52% vs. 55.91%, p  0.007) (63).
ubset analysis of Val-Heft (the Valsartan Heart Failure
rial) (64) and CHARM (Candesartan in Heart Failure)
65) showed a reduction in the incidence of AF in patients
eceiving ARBs compared with placebo (Table 5). In the
al-Heft trial, valsartan-treated patients had a 5.1% inci-
ence of AF versus 7.9% in the placebo arm (p  0.002).
he average ejection fraction in this study was approxi-
ately 27%. Similarly in the CHARM trial, patients with
oth normal and depressed ejection fraction were enrolled,
nd AF was reduced both in patients with depressed left
entricular function and in those with normal left ventric-
lar function.
onclusions
he understanding of the pathogenesis of AF is still
volving. The notion that the inflammatory process plays a
ole in AF has garnered much attention in many recent
tudies and is now a well-established connection. Many now
onsider inflammation to be an independent risk factor for
he initiation and maintenance of AF. Studies are currently
nderway in an attempt to attenuate the inflammatory
urden in patients with AF by novel therapeutic interven-
ions. Statins and ACE-Is/ARBs have shown the most
romise by modulating the inflammatory effects and inhib-
ting cardiac remodeling. Current evidence does not support
he administration of statins and ACE-Is/ARBs for the sole
urpose of preventing AF, because many of the current
ublished reports available were retrospective and observa-
ional in nature, with limited sample size. (28).eprint requests and correspondence: Dr. Nasser M. Lakkis,
rofessor of Medicine, 1709 Dryden, MS 9.90, Houston, Texas
7030. E-mail: nlakkis@bcm.tmc.edu.
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